Table 2.
Risk factors for HCC recurrence on univariate and multivariate Cox regression analysis.
| Variable | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | p | HR | 95%CI | p | |
| Age | 1.01 | 0.96–1.06 | 0.773 | |||
| Gender | 0.80 | 0.18–3.47 | 0.797 | |||
| Etiology | 0.90 | 0.56–1.44 | 0.660 | |||
| Pre LT RAF | 1.12 | 0.40–3.12 | 0.827 | |||
| Pre LT TACE | 1.67 | 0.63–4.42 | 0.307 | |||
| MELD | 1.01 | 0.96–1.06 | 0.658 | |||
| BMI (kg/m2) | 1.19 | 1.04–1.33 | 0.009 | 1.14 | 0.96–1.30 | 0.055 |
| AFP >1000 ng/ml | 6.66 | 1.93–23.04 | 0.003 | 10.05 | 2.45–41.13 | 0.001 |
| Tumor number | 2.10 | 1.31–3.23 | 0.002 | 2.08 | 1.25–3.47 | 0.005 |
| Max tumor diameter (cm) | 1.32 | 1.16–1.51 | <0.001 | 1.25 | 1.07–1.46 | 0.005 |
| Sum of tumor diameter (cm) | 1.23 | 1.11–1.36 | <0.001 | 0.85 | 0.60–1.20 | 0.366 |
| Microvascular invasion | 2.88 | 0.96–8.69 | 0.060 | 1.54 | 0.46–5.17 | 0.487 |
| TNM Stage | 1.88 | 1.27–2.78 | 0.002 | 1.16 | 0.61–2.18 | 0.652 |
LT, liver transplantation; RAF, radiofrequency ablation; TACE, transhepatic arterial chemotherapy and embolization; MELD, model for end-stage liver disease; BMI, body mass index; AFP, alpha-fetoprotein. Univariate and multivariate analyses were performed based on the Cox proportional hazards regression model. Clinical variables with a P of < 0.1 in the univariate analysis were included in the multivariate analysis.